Financial PerformanceAbbott Laboratories saw another beat/raise in Q2 with strong device growth in key franchises.
Product ExpansionWith Libre, Abbott continues to tap the significant opportunity for CGM utilization in basal insulin users, having secured favorable reimbursement for the indication in the US, Japan, France and Germany.
Revenue GrowthThe business posted 16.7% organic sales growth in 2Q, with double-digit growth in catheters and mapping-related products.